MTOR and cancer: KEGG pathway enrichment analysis of DEGs comparing high- and low-VGF expression groups in the TCGA-PRAD cohort demonstrated significant involvement of key oncogenic pathways, particularly the mTOR signaling pathway and the PD-L1 expression/PD-1 checkpoint pathway in cancer (Fig. 8B).